1296P Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio

Autor:	Toni Ibrahim, Silvia Vanni, Laura Mercatali, Jessica Menis, M.C. Pallotti, Valentina Fausti, M.R.C. Forcignanò, Flavia Foca, Chiara Spadazzi, M.C. Falasconi, M. Bertoni, Roberto Casadei, L.S. Stucci, Federica Recine, A. De Vita, Alberto Bongiovanni, Manuela Fantini, Fabrizio Artioli, V. Guadalupi
Rok vydání:	2021
Předmět:	Oncology business.industry medicine.medical_treatment Immune checkpoint inhibitors medicine Cancer research Hematology Neutrophil to lymphocyte ratio business Targeted therapy
Zdroj:	Annals of Oncology. 32:S1004-S1005
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1898
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ebd19a12e25a6e7f02a314dbf4d598fa https://doi.org/10.1016/j.annonc.2021.08.1898 Zobrazit plný text záznamu